The first two volumes of this peptide and longevity medicine series followed a clear structure. Volume One built the foundation: growth hormone, fat metabolism, tissue repair, immune function, and skin remodeling, six compounds addressing six distinct physiological systems within integrated aesthetic and longevity medicine. Volume Two went further into emerging research: completing the growth hormone optimization discussion, then covering telomere biology, neurological performance, anti-inflammatory pathways, and mitochondrial metabolism, five more compounds that each added a new layer to the treatment map DiFrancesco Plastic Surgery outlined at the close of that volume.

Together, those two volumes cover eleven posts and a coherent body of work representing most of what DiFrancesco Plastic Surgery prescribes and believes in as a practice built around integrated aesthetic medicine.

Then there were three topics that never fit neatly into that structure, the ones that kept coming up in patient conversations and consultations and needed their own honest, dedicated discussion. Those three topics make up Volume Three.

What Connects NAD+, PT-141, and Minoxidil Plus GHK-Cu

At first glance, NAD+, PT-141, and a minoxidil plus GHK-Cu topical protocol seem like an unusual grouping. One is a coenzyme, one is an FDA-approved sexual health peptide, and one is a hair restoration protocol. They do not share an obvious mechanism, and they do not fall into a single biological category the way the compounds in Volumes One and Two did.

What connects them instead is this: each one represents the most important clinical conversation that the first two volumes made necessary but had not yet addressed directly.

NAD+ became essential because of everything covered in Volume Two. After explaining Epitalon’s role in telomere biology, MOTS-C’s effect on mitochondrial insulin signaling, Semax’s influence on BDNF-driven neuroprotection, and Thymosin Alpha-1’s role in immune restoration, the natural next question is what fuels all of these systems. What keeps the cellular energy machinery running so that sirtuins stay active, DNA repair continues, and mitochondria produce ATP efficiently? The answer is NAD+. A complete integrated medicine series could not leave that question unanswered. NAD+ earned its own dedicated post because it underlies every biological system this series addresses, even though it is not technically a peptide.

PT-141 became necessary because of the goal of covering the whole patient. This series addresses how patients look and feel across every part of their health, and after fourteen posts on body composition, immune function, wound healing, cognitive performance, cellular aging, and hair restoration, sexual health could not be left out. Patients do not skip this conversation with their physician, and DiFrancesco Plastic Surgery was not willing to skip it in this series either. PT-141 is the only FDA-approved compound covered in the entire series, and excluding it because the subject calls for more clinical candor than typical wellness content would have gone against the exact editorial standard this publication is built on.

The minoxidil plus GHK-Cu topical protocol became necessary to close a gap in format. Every other post in this series explains what a compound is and what the research shows. This post instead explains what DiFrancesco Plastic Surgery actually prescribes in its hair restoration practice: the specific clinical combination used, the mechanisms that make the pairing effective together, and the decision-making framework applied to different patient presentations. Hair restoration is a central part of this practice and a deeply personal issue for the patients who come in describing one of the most emotionally significant changes happening to their bodies. The single-compound format used for the rest of the series could not fully capture how minoxidil and GHK-Cu work together in an actual protocol, so the final post in Volume Three takes a different approach. It is the series’ first true clinical combination post, still grounded in mechanism, and the most directly actionable content written so far for patients actively managing hair loss.

Three Posts, Three Gaps This Series Needed to Close

Volume Three is best understood as the completion volume, not the conclusion. This series will continue, and the regulatory landscape around these compounds is moving quickly enough that several earlier posts will likely need updates. Volume Three simply addresses the topics that a complete integrated medicine publication could not leave out.

The first gap: the cellular energy substrate that every biological system discussed earlier in the series depends on. The NAD+ post covers the coenzyme itself, the roughly 60 percent age-related decline in NAD+ levels, its connection to sirtuin and PARP activity, and an honest look at the current evidence, including findings from a 2026 systematic review describing the gap between consistent biochemical target engagement and variable functional outcomes in patients. The post also walks through the delivery method decision that shapes the clinical protocol, whether IV, subcutaneous injection, or an oral precursor is the right choice, and why that decision depends on where a patient is in their treatment plan.

The second gap: the sexual health conversation that integrated medicine owes its patients. The PT-141 post covers the neuroscience behind desire, results from the RECONNECT Phase 3 trial, an honest accounting of the response rate (25 to 30 percent, with a clear picture of which patients respond best), the nausea management strategies that determine whether patients stay on treatment, and the clinical distinctions that matter most: what PT-141 is indicated for, what it is not, and why an accurate diagnosis before prescribing is what actually produces results. It may be the most demanding post in the series for readers, because it treats sexual wellbeing as the clinical priority it is, rather than the afterthought it often becomes in aesthetic medicine.

The third gap: a real example of what physician-led combination therapy looks like in practice. The minoxidil plus GHK-Cu post is different from every other post in the series. Rather than a compound overview, it is a full clinical protocol covering the mechanism behind the combination, the evidence supporting it, the formulation decisions involved, the role of microneedling as an amplifier, a framework for selecting the right patients, and a realistic timeline for results. It is the post that most directly answers the question patients bring to DiFrancesco Plastic Surgery every week: “I’ve been using minoxidil. It’s not enough. What else can I do?” The answer is in this post, built on the same GHK-Cu mechanism first explained in Volume One.

What Has Changed Since Volume One

DiFrancesco Plastic Surgery published the first post in Volume One many months ago, and the regulatory landscape around compounded peptide medicine has shifted meaningfully since then.

The April 2026 FDA action that removed CJC-1295, BPC-157, TB-500, KPV, Semax, Epitalon, MOTS-C, and several other compounds from Category 2 restriction was the most significant regulatory change for compounded peptide medicine in years. The July 2026 Pharmacy Compounding Advisory Committee (PCAC) hearings that followed evaluated BPC-157 for ulcerative colitis, TB-500 for wound healing, KPV for inflammation, Semax for ischemia and migraine, Epitalon for insomnia, and MOTS-C for obesity and osteoporosis. These hearings represented the first formal FDA scientific review of these compounds for potential inclusion on the approved 503A bulk substances list, and the outcomes will shape the legal compounding landscape for years to come.

On July 23 and 24, the FDA’s Pharmacy Compounding Advisory Committee met at the agency’s White Oak campus to vote on whether seven peptides that had long occupied a legal gray area should be added to the 503A Bulk Drug Substance List, the list of ingredients that licensed compounding pharmacies are permitted to prepare against a prescription. For practices focused on integrated aesthetic and wellness medicine, this was the most significant peptide regulatory event of the year. Six of the seven compounds reviewed cleared: BPC-157, KPV, TB-500, MOTS-C, Semax, and Epitalon. Emideltide was rejected.

How to Approach Volume Three

Each of these three posts stands on its own. Readers do not need to have read Volumes One and Two to understand any of them, since each is written to be complete independently.

For readers following the series in order, the NAD+ post works well as a closing argument for the longevity-focused section. After reading about Epitalon, MOTS-C, and Semax, understanding the cellular energy substrate that all of those mechanisms rely on changes how the complete protocol picture comes together. It pairs well with the MOTS-C post for the mitochondrial angle and the Epitalon post for the sirtuin-telomere connection.

The PT-141 post stands entirely on its own and speaks to a patient population that may not overlap at all with readers interested in longevity and peptide therapy. Readers who came to this series for hair restoration, body composition, or hormone optimization and have not yet considered this topic may still find it relevant, either for themselves or someone they know. It is written for anyone managing sexual health as part of a complete wellness picture.

The minoxidil plus GHK-Cu post is written first and foremost for readers dealing with hair loss. Anyone actively managing hair loss, or advising someone who is, will find this the most immediately actionable post in the series. It pairs well with the Volume One post on GHK-Cu for the full mechanistic background on copper peptide biology.

What Comes After Volume Three

This series is not finished. The regulatory developments of mid-2026 alone have generated enough new clinical material for several follow-up posts. Once the PCAC outcomes are formally published, they will deserve a comprehensive update of their own. Additional compounds that have matured in the evidence base since this series began, including newer mitochondrial peptides, emerging exosome applications, and continued research in the Semax and nootropic space, are on the horizon for future posts.

More immediately, patients at DiFrancesco Plastic Surgery continue to raise questions this series has not yet answered, and those questions will shape the next posts. That is how physician-authored content should work: driven by clinical reality, updated as evidence evolves, and honest about what is and is not yet known at each stage.

The Editorial Standard Behind This Series

Across three volumes and sixteen posts, one standard has stayed constant. DiFrancesco Plastic Surgery reports when the evidence is strong and when it is still preliminary, names the PCAC votes that went against 503A inclusion, reports on Phase 2b trials that did not meet their endpoints, and distinguishes clearly between human clinical evidence and early preclinical findings.

That standard matters more today than when this series began. The peptide and longevity medicine space has attracted enough commercial and wellness marketing interest that the signal-to-noise ratio for patients trying to make informed decisions has become genuinely difficult to navigate. In that environment, a physician’s role is not to add to the noise, but to provide a calibrated, honest source of information that patients can actually use in their own care decisions.

That is the purpose of this publication, and Volume Three continues that commitment.

---